Clinical Trial Update: Ipromlimab and Tuvonralimab Combined With Albumin-Bound Paclitaxel and Nedaplatin as Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial update on neoadjuvant therapy combining ipromlimab and tuvonralimab with albumin-bound paclitaxel and nedaplatin for locally advanced, resectable …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Abraxane (albumin-bound paclitaxel) (paclitaxel protein-bound albumin)
• Ipromlimab (ipromlimab)
• Nedaplatin (nedaplatin)
• Tuvonralimab (tuvonralimab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Locally Advanced, Resectable | Phase 2 | Status: ACTIVE_NOT_RECRUITING